KIMBERLY CANADAY: Open Payments
NPI 1548280845 · FLORENCE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,021 in 137 payments from 41 companies in 2025. Trend: 2023 $2,554 · 2024 $2,893 · 2025 $3,021
Food & beverage: $3,021
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $526 |
| Novartis Pharmaceuticals Corporation | 21 | $416 |
| Janssen Biotech, Inc. | 10 | $213 |
| BeOne Medicines USA, Inc. | 9 | $168 |
| Merck Sharp & Dohme LLC | 7 | $156 |
| Janssen Scientific Affairs, LLC | 1 | $144 |
| E.R. Squibb & Sons, L.L.C. | 9 | $135 |
| PFIZER INC. | 7 | $119 |
| Celgene Corporation | 5 | $114 |
| ABBVIE INC. | 5 | $95 |
Products named: RYBREVANT, IMFINZI, KISQALI, KEYTRUDA, LYNPARZA, BRUKINSA, PLUVICTO, XTANDI.
Industry payments across AL — which companies pay providers there.
